Trials / Unknown
UnknownNCT05833802
Computation Prediction of Drug Response Based on Omics Data
A Companion Trial in Silico: Computing Drug Response for Cancer Patients in Clinical Trials（PRincipal-001)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 25 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to assess the performance of computational medicine technology in predicting patients response to anticancer drugs based on omics data.The main question it aims to answer is test consistency between the computing drug response and the response of real-world clinical trials. Participants will take part in silico.
Detailed description
A companion trial in silico was planned to compare head-to-head with a real clinical study of anti-tumor registered new drugs to verify the consistency between the efficacy prediction results of virtual clinical studies and the efficacy results of traditional clinical trials. Subjects simultaneously entered real world clinical trials and virtual clinical trials built by computer modeling and artificial intelligence technology. The results of traditional clinical trials were compared with those of virtual clinical trials to calculate the consistency of virtual clinical trials. By predicting the population with consistent efficacy, locking the response population to new drugs, using the innovative technology of computational medicine, grasping the omics characteristics of the response population, and using this as a starting point to determine the target population of clinical trials, so as to determine new screening conditions, design new clinical trials, accurately match the effective population, and revolutionary change the efficiency of clinical trials, thereby shortening the process and cost of clinical trial development.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | virtual anti-cancer drug | the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology |
Timeline
- Start date
- 2023-02-15
- Primary completion
- 2024-05-15
- Completion
- 2024-09-15
- First posted
- 2023-04-27
- Last updated
- 2023-04-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05833802. Inclusion in this directory is not an endorsement.